Literature DB >> 16585215

CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta.

Masaki Terabe1, Chand Khanna, Seuli Bose, Fraia Melchionda, Arnulfo Mendoza, Crystal L Mackall, Lee J Helman, Jay A Berzofsky.   

Abstract

It has been shown previously that the suppression of tumor immunosurveillance may be a mechanism by which tumors resist immune detection and elimination. In this study, we evaluated the role of the immunoregulatory natural killer T (NKT) cells in the biology of immunosurveillance of osteosarcoma. The K7M2 mouse osteosarcoma cell line was implanted orthotopically into wild-type and NKT cell-deficient CD1d knockout (KO) BALB/c mice, and mice were monitored for growth of primary tumors. Further, we examined the role of CD4(+) and/or CD8(+) cells by depleting the cells in vivo and measuring CTL activity in vitro. We also asked the role of interleukin (IL)-4 receptor alpha (IL-4Ralpha)-signal transducer and activator of transcription 6 (STAT6) signaling, including IL-13, and transforming growth factor beta (TGF-beta) by using gene-disrupted mice or treating mice with cytokine antagonists. We were surprised to find a high rate of rejection of osteosarcoma primary tumors in 88% (14 of 16) of CD1d KO mice compared with syngeneic wild-type BALB/c mice that showed rejection of tumor in <24% of mice. Further studies suggested that the rejection of tumor in CD1d KO mice was dependent on CD8(+) lymphocytes. Distinct from other murine tumor models, the negative regulation induced by CD1d-restricted NKT cells was not dependent on IL-4Ralpha-STAT6 signaling, including IL-13, or on TGF-beta. These data suggest that a novel CD1d-restricted NKT cell-mediated mechanism for tumor immunosuppression is active in the K7M2 osteosarcoma model and that NKT cells can regulate immunosurveillance through more than one pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16585215     DOI: 10.1158/0008-5472.CAN-05-3421

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Impacts of the MHC class I-like XNC10 and innate-like T cells on tumor tolerance and rejection in the amphibian Xenopus.

Authors:  Maureen Banach; Eva-Stina Edholm; Xavier Gonzalez; Abdellatif Benraiss; Jacques Robert
Journal:  Carcinogenesis       Date:  2019-07-20       Impact factor: 4.944

2.  Invariant NKT cells increase drug-induced osteosarcoma cell death.

Authors:  S Fallarini; T Paoletti; N Orsi Battaglini; G Lombardi
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

Review 3.  Type II NKT Cells and Their Emerging Role in Health and Disease.

Authors:  Madhav V Dhodapkar; Vipin Kumar
Journal:  J Immunol       Date:  2017-02-01       Impact factor: 5.422

Review 4.  Lymphocytes in cancer development: polarization towards pro-tumor immunity.

Authors:  Brian Ruffell; David G DeNardo; Nesrine I Affara; Lisa M Coussens
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-11       Impact factor: 7.638

5.  Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade.

Authors:  Karsten A Pilones; Noriko Kawashima; Anne Marie Yang; James S Babb; Silvia C Formenti; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

6.  Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells.

Authors:  Shun Takaku; Masaki Terabe; Elena Ambrosino; Judy Peng; Scott Lonning; John M McPherson; Jay A Berzofsky
Journal:  Int J Cancer       Date:  2010-04-01       Impact factor: 7.396

Review 7.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

8.  CD1d activation and blockade: a new antitumor strategy.

Authors:  Michele W L Teng; Simon Yue; Janelle Sharkey; Mark A Exley; Mark J Smyth
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

9.  Gene Therapy against Murine Melanoma B16F10-Nex2 Using IL-13Ralpha2-Fc Chimera and Interleukin 12 in Association with a Cyclopalladated Drug.

Authors:  Flavia Hebeler-Barbosa; Elaine G Rodrigues; Rosana Puccia; Antonio Cf Caires; Luiz R Travassos
Journal:  Transl Oncol       Date:  2008-09       Impact factor: 4.243

Review 10.  The contrasting roles of NKT cells in tumor immunity.

Authors:  Jay A Berzofsky; Masaki Terabe
Journal:  Curr Mol Med       Date:  2009-08       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.